Loading patent…
AssigneeAlexza Molecular Delivery Corporation
InventorsRon L. Hale, Joshua D. Rabinowitz, Dennis W. Solas, Alejandro C. Zaffaroni
Estimating the term…
The present invention relates to the delivery of headache and anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing that are used in inhalation therapy. In a method aspect of the present invention, rizatriptan or zolmitriptan is administered to a patient through an inhalation route. The method comprises: a) heating a composition, comprising rizatriptan or zolmitriptan to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol with less than 5% of the drug degradation products. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route is provided which comprises: a) a thin coating of a rizatriptan or zolmitriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.
A method of treating headache or migraine comprising administering a therapeutic amount of a rizatriptan or zolmitriptan condensation aerosol, having an MMAD less than 3 μm and less than 5% rizatriptan or zolmitriptan degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
A method of administering rizatriptan or zolmitriptan to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of rizatriptan or zolmitriptan having less than 5% rizatriptan or zolmitriptan products and an MMAD less than 3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.
A kit for delivering a drug aerosol comprising:
Dependencies are inferred from the claim text.